AMENDMENT TO THE CLAIMS

Claim 1. (Canceled)

Claim 2. (Canceled): A compound which is an inhibitor of the PKC, in free form or in a pharmaceutically acceptable salt form, wherein said compound possesses a selectivity for the PKC over one or more protein kinases which do not belong to the CDK-family, and a selectivity for the PKCα, PKCβ and optionally PKCθ, over one or more of the other PKC isoforms of at least 10 fold, as measured by the ratio of the IC_{50} of the compound for a PKC which is not α and β, and optionally not θ, to the IC_{50} of the compound for the PKCα, PKCβ or PKC θ, respectively.

Claim 3. (Canceled):.A compound which is an inhibitor of the PKC, in free form or in a pharmaceutically acceptable salt form, wherein said compound possesses a selectivity for PKCα, PKCβ and optionally PKCθ, over one or more of the other PKC isoforms of at least 10 fold, and for which the ratio of the IC_{50} value as determined by Allogeneic Mixed Lymphocyte Reaction (MLR) assay to the IC_{50} value as determined by Bone Marrow proliferative (BM) assay is higher than 5.

Claim 4. (Canceled): A compound which is an inhibitor of the PKC, in free form or in a pharmaceutically acceptable salt form, wherein said compound possesses a selectivity for the PKCα, PKCβ and PKCθ, over one or more of the other PKC isoforms of at least 10 fold, as measured according to claim 2.

Claim 5. (Previously presented): A compound of formula I



wherein

R_a is H; C_{1-4}alkyl; or C_{1-4}alkyl substituted by OH, NH_2, NHC_{1-4}alkyl or $N(di\text{-}C_{1-4}alkyl)_2$;

one of R_b, R_c, R_d and R_e is halogen; C_{1-4}alkoxy; C_{1-4}alkyl; CF_3 or CN and the other three

substituents are each H; or R_b, R_c, R_d and R_e are all H; and

R is a radical of formula (a), (b) or (c)



(a)



(b)



(c)

wherein

R_1 is $-(CH_2)_n-NR_3R_4$,

wherein

each of R_3 and R_4, independently, is H or C_{1-4}alkyl; or R_3 and R_4 form together with the nitrogen atom to which they are bound a heterocyclic residue;

n is 0, 1 or 2; and

R_2 is H; halogen; C_{1-4}alkyl; CF_3: OH; SH; NH_2; C_{1-4}alkoxy; C_{1-4}alkylthio; NHC_{1-4}alkyl; $N(di\text{-}C_{1-4}alkyl)_2$, CN, alkyne or NO_2;

wherein

each of R_{10} and R_{10a}, independently, is a heterocyclic residue; or a radical of formula α

$$-X-R_f-Y \qquad (\alpha)$$

wherein X is a direct bond, O, S or NR_{11} wherein R_{11} is H or C_{1-4}alkyl,

R_f is C_{1-4}alkylene or C_{1-4}akylene wherein one CH_2 is replaced by CR_xR_y wherein one of R_x and R_y is H and the other is CH_3 each of R_x and R_y is CH_3 or R_x and R_y form together $-CH_2-CH_2-$,

Y is bound to the terminal carbon atom and is selected from OH, $-NR_{30}R_{40}$ wherein each of R_{30} and R_{40}, independently, is H, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, aryl-C_{1-4}alkyl, heteroaryl-C_{1-4}alkyl, C_{2-6}alkenyl or C_{1-4}alkyl optionally substituted on the terminal carbon atom by OH, halogen, C_{1-4}alkoxy or $-NR_{50}R_{60}$ wherein each of R_{50} and R_{60}, independently, is H, C_{1-4}alkyl,

C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, aryl-C_{1-4}alkyl, or R_{30} and R_{40} form together with the nitrogen atom to which they are bound a heterocyclic residue; and

each of R_{20} and R_{20a}, independently, is H; halogen; C_{1-4}alkyl; C_{1-4}alkoxy; CF_3; nitrile; nitro or amino;

or a salt thereof.

Claim 6. (Currently amended): [[A]] The compound according to claim 5, wherein R_a is H or methyl; each of R_2, R_{20} and R_{20a}, independently, is H, Cl, NO_2, F, CF_3 or methyl, n is o or 1; one of R_b, R_c, R_d and R_e is methyl or ethyl and the other three substituents are H; or R_b, R_c. R_d and R_e are all H; and each of R_3 and R_4, independently, is H, methyl, ethyl or *i*-propyl; or R_3 and R_4 form together with the nitrogen atom to which they are bound a heterocyclic residue optionally substituted; and each of R_1, R_{10} and R_{10a}, independently, is a heterocyclic residue.

Claim 7. (Currently amended): [[A]] The compound according to claim 5, which is selected from

3-[5-Chloro-2-(4-methyl-piperazin-1-yl)-pyridin-4-yl]-4-(1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7-dimethylaminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(7-Aminomethyl-2-Chloro-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7-methylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7-methylaminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7-methylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7-methylaminomethyl-naphthalen-1-yl)-4-(6-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7-methylaminomethyl-naphthalen-1-yl)-4-(5-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7- dimethylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7-dimethylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7- dimethylaminomethyl-naphthalen-1-yl)-4-(6-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7- dimethylaminomethyl-naphthalen-1-yl)-4-(5-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-{2-Chloro-7-[(ethyl-methyl-amino)-methyl]-naphthalen-1-yl}-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7-diethylaminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7-ethylaminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-[2-Chloro-7-(isopropylamino- methyl)-naphthalen-1-yl]-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-[2-Chloro-7-(4-methyl-piperazin-1-ylmethyl) naphthalen-1-yl] -4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-7- pyrrolidin-1-ylmethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(7-Aminomethyl-2-methyl-naphthalen-1-yl)-4-(1,7-dimethyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(7-Aminomethyl-2-methyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(7-Aminomethyl-2-methyl -naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;

3-(7-Aminomethyl-2-methyl -naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(7-Aminomethyl -naphthalen-1-yl)-4-(1-H-indol-3-yl)-pyrrole-2,5-dione;

3-(7-Aminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(7-Amino-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(7-Amino-naphthalen-1-yl)-4-(1H -indol-3-yl)-pyrrole-2,5-dione;

3-(7-Dimethylaminomethyl-2-fluoro-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(7-dimethylaminomethyl-2-fluoro-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;

3-(1-Methyl-1H-indol-3-yl)-4-[5-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-pyrrole-2,5-dione;

3-(1H-indol-3-yl)-4-[5-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-pyrrole-2,5-dione;

3-(7-methyl-1H-indol-3-yl)-4-[5-(4-methyl-piperazin-1-yl)-2-trifluoromethyl-pyridin-3-yl]-pyrrole-2,5-dione;

3-(1H-indol-3-yl)-4-[5-(4-methyl-piperazin-1-yl)-2-trifluoromethyl-pyridin-3-yl]-pyrrole-2,5-dione;
3-(1-methyl-1H-indol-3-yl)-4-[5-(4-methyl-piperazin-1-yl)-2-trifluoromethyl-pyridin-3-yl]-pyrrole-2,5-dione;
3-(7-methyl-1H-indol-3-yl)-4-[5-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-4-[5-(4-methyl-piperazin-1-yl)-2-nitro-pyridin-3-yl]-pyrrole-2,5-dione;
3-[2-chloro-5-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-4-[5-methyl-2-(4-methyl-piperazin-1-yl)-pyridin-4-yl]-pyrrole-2,5-dione;
3-(1H-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-5-nitro-pyridin-4-yl]-pyrrole-2,5-dione; and
3-(1H-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-5-trifluoromethyl-pyridin-4-yl]-pyrrole-2,5-dione; in free form or in a pharmaceutically acceptable salt form.

Claim 8. (Currently amended): [[A]] The compound according to claim 5, in free form or in a pharmaceutically acceptable salt form, for use as a pharmaceutical.

Claim 9. (Canceled): A compound according to claim 2, for treating or preventing diseases or disorders mediated by T lymphocytes and/or PKC, in particular allograft rejection, graft versus host disease, autoimmune diseases, infectious diseases, inflammatory diseases, cardiovascular diseases or cancer.

Claim 10. (Canceled): A pharmaceutical composition comprising a compound according to claim 2, in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable diluent or carrier therefor.

Claim 11. (Canceled)

Claim 12. (Canceled): A pharmaceutical combination comprising a compound according to claim 2, in free form or in a pharmaceutically acceptable salt form, and a further agent selected from immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic. antiproliferative and anti-diabetic agents.

Claim 13. (Currently amended): A process for the production of [[a]] the compound according to claim 5, wherein the ~~which~~ process comprises reacting a compound of formula *II*



II

wherein R_a to R_e are as defined in claim 5,

with a compound of formula III

$$R - CH_2 - CO - NH_2 \qquad (III)$$

wherein R is as defined in claim 5,

and, where required, converting the resulting compound of formula I obtained in free form to a salt form or vice versa, as appropriate.

Claim 14. (Canceled): A method for treating or preventing disorders or diseases mediated by T lymphocytes and/or PKC, in particular allograft rejection, graft versus host disease, autoimmune diseases, infectious diseases, inflammatory diseases, cardiovascular diseases or cancer, in a subject in need of such a treatment, which method comprises administering to said subject an effective amount of an inhibitor of PKC which possesses a selectivity for PKCα, PKCβ and optionally PKCθ, over one or more of the other PKC isoforms of at least 10 fold, as measured according to claim 2, or a pharmaceutically acceptable salt thereof.

Claim 15. (Canceled): A method for treating or preventing disorders or diseases mediated by T lymphocytes and/or PKC, in particular allograft rejection, graft versus host disease, autoimmune diseases, infectious diseases, inflammatory diseases, cardiovascular diseases or cancer, in a subject in need of such a treatment, which method comprises administering to said subject an effective amount of a compound according to claim 2, or a pharmaceutically acceptable salt thereof.